Disease · MONDO_0007739
Trials72
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
1 to 20 of 72
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03761849 | A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease | Phase 3 | 899 | 2023-11-07 | Huntingtons Disease | TOMINERSEN | Its record names the disease | ClinicalTrials.gov |
| NCT00608881 | Coenzyme Q10 in Huntington's Disease (HD) | Phase 3 | 609 | 2016-03-30 | Huntington's Disease | UBIDECARENONE | Its record names the disease | ClinicalTrials.gov |
| NCT04556656 | PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD | Phase 3 | 499 | 2025-03-12 | Huntington Disease | PRIDOPIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT00665223 | A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease | Phase 3 | 437 | 2023-08-29 | Huntington's Disease | PRIDOPIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT02006472 | A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease | Phase 2 | 408 | 2021-07-19 | Huntington's Disease | PRIDOPIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT02215616 | A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod | Phase 2 | 352 | 2019-06-19 | Huntington's Disease | LAQUINIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT02197130 | Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease | Phase 2 | 272 | 2017-11-17 | Huntington's Disease | MARDEPODECT | Its record names the disease | ClinicalTrials.gov |
| NCT02494778 | A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease | Phase 2 | 248 | 2021-09-17 | Huntington's Disease | PRIDOPIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT03842969 | An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies | Phase 3 | 236 | 2023-08-31 | Huntington Disease | TOMINERSEN | Its record names the disease | ClinicalTrials.gov |
| NCT00724048 | A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease | Phase 2 | 227 | 2023-08-31 | Huntington Disease | PRIDOPIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT05107128 | A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) | Phase 2 | 189 | 2025-09-05 | Huntington's Disease | DALZANEMDOR | Its record names the disease | ClinicalTrials.gov |
| NCT02342548 | Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021 | Phase 2 | 188 | 2018-04-23 | Huntington's Disease | MARDEPODECT | Its record names the disease | ClinicalTrials.gov |
| NCT05358717 | A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD) | Phase 2 | 159 | 2026-01-13 | Huntington Disease | VOTOPLAM | Its record names the disease | ClinicalTrials.gov |
| NCT05655520 | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease | Phase 3 | 153 | 2025-12-17 | Huntington's Disease | DALZANEMDOR | Its record names the disease | ClinicalTrials.gov |
| NCT05475483 | Efficacy and Safety on SOM3355 in Huntington's Disease Chorea | Phase 2 | 139 | 2025-08-28 | Huntington Chorea | BEVANTOLOL HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01306929 | Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease | Phase 2 | 134 | 2022-02-09 | Huntington Disease | PRIDOPIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT01897896 | Alternatives for Reducing Chorea in Huntington Disease | Phase 3 | 119 | 2019-04-16 | Chorea Associated With Huntington Disease | DEUTETRABENAZINE | Its record names the disease | ClinicalTrials.gov |
| NCT00277355 | Pilot Study of Minocycline in Huntington's Disease | Phase 2/3 | 114 | 2013-04-19 | Huntington Disease | MINOCYCLINE | Its record names the disease | ClinicalTrials.gov |
| NCT02507284 | Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease | Phase 2 | 106 | 2023-07-20 | Irritable Mood, Huntington's Disease | SRX246 | Its record names the disease | ClinicalTrials.gov |
| NCT01795859 | First Time Use of SD-809 in Huntington Disease | Phase 3 | 90 | 2017-08-11 | Chorea | DEUTETRABENAZINE | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007739/trials